APO Research
Talk to an analyst

APO RESEARCH · REPORT

Soliris (Eculizumab)

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.

Selected research

Market Analysis & Forecast

Global Soliris (Eculizumab) Market Analysis and Forecast 2026-2032

20 December 2025198 pages

Choose your research edition.

Industry ResearchSoliris (Eculizumab) Industry Research Report 2026104 pages · $2,950 USDIndustry Growth & TrendsGlobal Soliris (Eculizumab) Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal Soliris (Eculizumab) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Soliris (Eculizumab) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Soliris (Eculizumab) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.

In Asia-Pacific, Japan is the largest Soliris (Eculizumab) market with about 32% market share. China is follower, accounting for about 25% market share.The key manufacturers are Alexion etc.

Report Includes

Read the full market overview

This report presents an overview of global market for Soliris (Eculizumab), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Soliris (Eculizumab), also provides the revenue of main regions and countries. Of the upcoming market potential for Soliris (Eculizumab), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Soliris (Eculizumab) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Soliris (Eculizumab) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Soliris (Eculizumab) revenue, projected growth trends, production technology, application and end-user industry.

Soliris (Eculizumab) Segment by Company

Alexion

Soliris (Eculizumab) Segment by Type

Plasma Exchange

Plasma Infusion

Soliris (Eculizumab) Segment by Application

PNH

aHUS

Others

Soliris (Eculizumab) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Soliris (Eculizumab) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Soliris (Eculizumab) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Soliris (Eculizumab).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Soliris (Eculizumab) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Soliris (Eculizumab) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Soliris (Eculizumab) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Soliris (Eculizumab) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Plasma Exchange Major Player Table 3. Plasma Infusion Major Player Table 4. Global Soliris (Eculizumab) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. PNH Major Player Table 6. aHUS Major Player Table 7. Others Major Player Table 8. Soliris (Eculizumab) Industry Trends Table 9. Soliris (Eculizumab) Industry Drivers Table 10. Soliris (Eculizumab) Industry Opportunities and Challenges Table 11. Soliris (Eculizumab) Industry Restraints Table 12. Global Soliris (Eculizumab) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Soliris (Eculizumab) Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Soliris (Eculizumab) Market Share by Region (2021-2026) Table 15. Global Soliris (Eculizumab) Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Soliris (Eculizumab) Market Share by Region (2027-2032) Table 17. Global Soliris (Eculizumab) Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Soliris (Eculizumab) Revenue Market Share by Players (2021-2026) Table 19. Global Soliris (Eculizumab) Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Soliris (Eculizumab) Key Players Headquarters & Area Served Table 21. Global Soliris (Eculizumab) Players, Product Type & Application Table 22. Global Soliris (Eculizumab) Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Soliris (Eculizumab) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Soliris (Eculizumab) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Soliris (Eculizumab) Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Soliris (Eculizumab) Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Soliris (Eculizumab) Revenue Market Share by Type (2021-2026) Table 29. Global Soliris (Eculizumab) Revenue Market Share by Type (2027-2032) Table 30. Global Soliris (Eculizumab) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Soliris (Eculizumab) Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Soliris (Eculizumab) Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Soliris (Eculizumab) Revenue Market Share by Application (2021-2026) Table 34. Global Soliris (Eculizumab) Revenue Market Share by Application (2027-2032) Table 35. Alexion Company Information Table 36. Alexion Business Overview Table 37. Alexion Soliris (Eculizumab) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Alexion Soliris (Eculizumab) Product Portfolio Table 39. Alexion Recent Development Table 40. North America Soliris (Eculizumab) Revenue by Type (2021-2026) & (US$ Million) Table 41. North America Soliris (Eculizumab) Revenue by Type (2027-2032) & (US$ Million) Table 42. North America Soliris (Eculizumab) Revenue by Application (2021-2026) & (US$ Million) Table 43. North America Soliris (Eculizumab) Revenue by Application (2027-2032) & (US$ Million) Table 44. North America Soliris (Eculizumab) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 45. North America Soliris (Eculizumab) Revenue by Country (2021-2026) & (US$ Million) Table 46. North America Soliris (Eculizumab) Revenue by Country (US$ Million) & (2027-2032) Table 47. Europe Soliris (Eculizumab) Revenue by Type (2021-2026) & (US$ Million) Table 48. Europe Soliris (Eculizumab) Revenue by Type (2027-2032) & (US$ Million) Table 49. Europe Soliris (Eculizumab) Revenue by Application (2021-2026) & (US$ Million) Table 50. Europe Soliris (Eculizumab) Revenue by Application (2027-2032) & (US$ Million) Table 51. Europe Soliris (Eculizumab) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Europe Soliris (Eculizumab) Revenue by Country (2021-2026) & (US$ Million) Table 53. Europe Soliris (Eculizumab) Revenue by Country (US$ Million) & (2027-2032) Table 54. China Soliris (Eculizumab) Revenue by Type (2021-2026) & (US$ Million) Table 55. China Soliris (Eculizumab) Revenue by Type (2027-2032) & (US$ Million) Table 56. China Soliris (Eculizumab) Revenue by Application (2021-2026) & (US$ Million) Table 57. China Soliris (Eculizumab) Revenue by Application (2027-2032) & (US$ Million) Table 58. Asia Soliris (Eculizumab) Revenue by Type (2021-2026) & (US$ Million) Table 59. Asia Soliris (Eculizumab) Revenue by Type (2027-2032) & (US$ Million) Table 60. Asia Soliris (Eculizumab) Revenue by Application (2021-2026) & (US$ Million) Table 61. Asia Soliris (Eculizumab) Revenue by Application (2027-2032) & (US$ Million) Table 62. Asia Soliris (Eculizumab) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 63. Asia Soliris (Eculizumab) Revenue by Region (US$ Million) & (2021-2026) Table 64. Asia Soliris (Eculizumab) Revenue by Region (US$ Million) & (2027-2032) Table 65. SAMEA Soliris (Eculizumab) Revenue by Type (2021-2026) & (US$ Million) Table 66. SAMEA Soliris (Eculizumab) Revenue by Type (2027-2032) & (US$ Million) Table 67. SAMEA Soliris (Eculizumab) Revenue by Application (2021-2026) & (US$ Million) Table 68. SAMEA Soliris (Eculizumab) Revenue by Application (2027-2032) & (US$ Million) Table 69. SAMEA Soliris (Eculizumab) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. SAMEA Soliris (Eculizumab) Revenue by Country (2021-2026) & (US$ Million) Table 71. SAMEA Soliris (Eculizumab) Revenue by Country (US$ Million) & (2027-2032) Table 72. Research Programs/Design for This Report Table 73. Authors List of This Report Table 74. Secondary Sources Table 75. Primary Sources List of Figures Figure 1. Soliris (Eculizumab) Image Figure 2. Global Soliris (Eculizumab) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Soliris (Eculizumab) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Plasma Exchange Image Figure 5. Plasma Infusion Image Figure 6. Global Soliris (Eculizumab) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Soliris (Eculizumab) Market Size Share 2021 VS 2025 VS 2032 Figure 8. PNH Image Figure 9. aHUS Image Figure 10. Others Image Figure 11. Global Soliris (Eculizumab) Market Size (US$ Million) & (2021-2032) Figure 12. Global Soliris (Eculizumab) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Soliris (Eculizumab) Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Soliris (Eculizumab) Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Soliris (Eculizumab) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Soliris (Eculizumab) Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Soliris (Eculizumab) Revenue Market Share by Type (2021-2032) Figure 19. Global Soliris (Eculizumab) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Soliris (Eculizumab) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Soliris (Eculizumab) Revenue Market Share by Application (2021-2032) Figure 22. North America Soliris (Eculizumab) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Soliris (Eculizumab) Revenue Share by Type (2021-2032) Figure 24. North America Soliris (Eculizumab) Revenue Share by Application (2021-2032) Figure 25. North America Soliris (Eculizumab) Revenue Share by Country (2021-2032) Figure 26. United States Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Soliris (Eculizumab) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Soliris (Eculizumab) Revenue Share by Type (2021-2032) Figure 31. Europe Soliris (Eculizumab) Revenue Share by Application (2021-2032) Figure 32. Europe Soliris (Eculizumab) Revenue Share by Country (2021-2032) Figure 33. Germany Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Soliris (Eculizumab) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Soliris (Eculizumab) Revenue Share by Type (2021-2032) Figure 43. China Soliris (Eculizumab) Revenue Share by Application (2021-2032) Figure 44. Asia Soliris (Eculizumab) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Soliris (Eculizumab) Revenue Share by Type (2021-2032) Figure 46. Asia Soliris (Eculizumab) Revenue Share by Application (2021-2032) Figure 47. Asia Soliris (Eculizumab) Revenue Share by Region (2021-2032) Figure 48. Japan Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Soliris (Eculizumab) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Soliris (Eculizumab) Revenue Share by Type (2021-2032) Figure 56. SAMEA Soliris (Eculizumab) Revenue Share by Application (2021-2032) Figure 57. SAMEA Soliris (Eculizumab) Revenue Share by Country (2021-2032) Figure 58. Brazil Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Soliris (Eculizumab) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Plasma Exchange
  • Plasma Infusion
Applications
  • PNH
  • aHUS
  • Others
Companies covered
  • Alexion

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Soliris (Eculizumab) Market by Type
  3. 1.2.1 Global Soliris (Eculizumab) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Plasma Exchange
  5. 1.2.3 Plasma Infusion
  6. 1.3 Soliris (Eculizumab) Market by Application
  7. 1.3.1 Global Soliris (Eculizumab) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 PNH
  9. 1.3.3 aHUS
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Soliris (Eculizumab) Market Dynamics
  1. 2.1 Soliris (Eculizumab) Industry Trends
  2. 2.2 Soliris (Eculizumab) Industry Drivers
  3. 2.3 Soliris (Eculizumab) Industry Opportunities and Challenges
  4. 2.4 Soliris (Eculizumab) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Soliris (Eculizumab) Market Perspective (2021-2032)
  2. 3.2 Global Soliris (Eculizumab) Growth Trends by Region
  3. 3.2.1 Global Soliris (Eculizumab) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Soliris (Eculizumab) Market Size by Region (2021-2026)
  5. 3.2.3 Global Soliris (Eculizumab) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Soliris (Eculizumab) Revenue by Players
  2. 4.1.1 Global Soliris (Eculizumab) Revenue by Players (2021-2026)
  3. 4.1.2 Global Soliris (Eculizumab) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Soliris (Eculizumab) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Soliris (Eculizumab) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Soliris (Eculizumab) Key Players Headquarters & Area Served
  7. 4.4 Global Soliris (Eculizumab) Players, Product Type & Application
  8. 4.5 Global Soliris (Eculizumab) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Soliris (Eculizumab) Market CR5 and HHI
  11. 4.6.3 2025 Soliris (Eculizumab) Tier 1, Tier 2, and Tier 3
5 Soliris (Eculizumab) Market Size by Type
  1. 5.1 Global Soliris (Eculizumab) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Soliris (Eculizumab) Revenue by Type (2021-2032)
  3. 5.3 Global Soliris (Eculizumab) Revenue Market Share by Type (2021-2032)
6 Soliris (Eculizumab) Market Size by Application
  1. 6.1 Global Soliris (Eculizumab) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Soliris (Eculizumab) Revenue by Application (2021-2032)
  3. 6.3 Global Soliris (Eculizumab) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Alexion
  2. 7.1.1 Alexion Company Information
  3. 7.1.2 Alexion Business Overview
  4. 7.1.3 Alexion Soliris (Eculizumab) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Alexion Soliris (Eculizumab) Product Portfolio
  6. 7.1.5 Alexion Recent Developments
8 North America
  1. 8.1 North America Soliris (Eculizumab) Revenue (2021-2032)
  2. 8.2 North America Soliris (Eculizumab) Revenue by Type (2021-2032)
  3. 8.2.1 North America Soliris (Eculizumab) Revenue by Type (2021-2026)
  4. 8.2.2 North America Soliris (Eculizumab) Revenue by Type (2027-2032)
  5. 8.3 North America Soliris (Eculizumab) Revenue Share by Type (2021-2032)
  6. 8.4 North America Soliris (Eculizumab) Revenue by Application (2021-2032)
  7. 8.4.1 North America Soliris (Eculizumab) Revenue by Application (2021-2026)
  8. 8.4.2 North America Soliris (Eculizumab) Revenue by Application (2027-2032)
  9. 8.5 North America Soliris (Eculizumab) Revenue Share by Application (2021-2032)
  10. 8.6 North America Soliris (Eculizumab) Revenue by Country
  11. 8.6.1 North America Soliris (Eculizumab) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Soliris (Eculizumab) Revenue by Country (2021-2026)
  13. 8.6.3 North America Soliris (Eculizumab) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Soliris (Eculizumab) Revenue (2021-2032)
  2. 9.2 Europe Soliris (Eculizumab) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Soliris (Eculizumab) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Soliris (Eculizumab) Revenue by Type (2027-2032)
  5. 9.3 Europe Soliris (Eculizumab) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Soliris (Eculizumab) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Soliris (Eculizumab) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Soliris (Eculizumab) Revenue by Application (2027-2032)
  9. 9.5 Europe Soliris (Eculizumab) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Soliris (Eculizumab) Revenue by Country
  11. 9.6.1 Europe Soliris (Eculizumab) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Soliris (Eculizumab) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Soliris (Eculizumab) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Soliris (Eculizumab) Revenue (2021-2032)
  2. 10.2 China Soliris (Eculizumab) Revenue by Type (2021-2032)
  3. 10.2.1 China Soliris (Eculizumab) Revenue by Type (2021-2026)
  4. 10.2.2 China Soliris (Eculizumab) Revenue by Type (2027-2032)
  5. 10.3 China Soliris (Eculizumab) Revenue Share by Type (2021-2032)
  6. 10.4 China Soliris (Eculizumab) Revenue by Application (2021-2032)
  7. 10.4.1 China Soliris (Eculizumab) Revenue by Application (2021-2026)
  8. 10.4.2 China Soliris (Eculizumab) Revenue by Application (2027-2032)
  9. 10.5 China Soliris (Eculizumab) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Soliris (Eculizumab) Revenue (2021-2032)
  2. 11.2 Asia Soliris (Eculizumab) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Soliris (Eculizumab) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Soliris (Eculizumab) Revenue by Type (2027-2032)
  5. 11.3 Asia Soliris (Eculizumab) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Soliris (Eculizumab) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Soliris (Eculizumab) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Soliris (Eculizumab) Revenue by Application (2027-2032)
  9. 11.5 Asia Soliris (Eculizumab) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Soliris (Eculizumab) Revenue by Country
  11. 11.6.1 Asia Soliris (Eculizumab) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Soliris (Eculizumab) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Soliris (Eculizumab) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Soliris (Eculizumab) Revenue (2021-2032)
  2. 12.2 SAMEA Soliris (Eculizumab) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Soliris (Eculizumab) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Soliris (Eculizumab) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Soliris (Eculizumab) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Soliris (Eculizumab) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Soliris (Eculizumab) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Soliris (Eculizumab) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Soliris (Eculizumab) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Soliris (Eculizumab) Revenue by Country
  11. 12.6.1 SAMEA Soliris (Eculizumab) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Soliris (Eculizumab) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Soliris (Eculizumab) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst